Primary Biliary Cholangitis Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Report ID: 248726 | Published Date: Jan 2025 | No. of Page: 99 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
Table of Contents
1  RESEARCH SCOPE
    1.1 Research Product Definition
    1.2 Research Segmentation
        1.2.1 Product Type
        1.2.2 Main product Type of Major Players
    1.3 Demand Overview
    1.4 Research Methodology
2 GLOBAL PRIMARY BILIARY CHOLANGITIS TREATMENT INDUSTRY
    2.1 Summary about Primary Biliary Cholangitis Treatment Industry
    2.2 Primary Biliary Cholangitis Treatment Market Trends
        2.2.1 Primary Biliary Cholangitis Treatment Production & Consumption Trends
        2.2.2 Primary Biliary Cholangitis Treatment Demand Structure Trends
    2.3 Primary Biliary Cholangitis Treatment Cost & Price
3  MARKET DYNAMICS
    3.1 Manufacturing & Purchasing Behavior in 2020
    3.2 Market Development under the Impact of COVID-19
        3.2.1 Drivers
        3.2.2 Restraints
        3.2.3 Opportunity
        3.2.4 Risk
4  GLOBAL MARKET SEGMENTATION
    4.1 Region Segmentation (2017 to 2021f)
        4.1.1 North America (U.S., Canada and Mexico)
        4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
        4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
        4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
        4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
    4.2 Product Type Segmentation (2017 to 2021f)
        4.2.1 Ursodeoxycholic Acid (UDCA)
        4.2.2 Obeticholic Acid (Ocaliva)
    4.3 Consumption Segmentation (2017 to 2021f)
        4.3.1 Hospitals
        4.3.2 Clinics
        4.3.3 Others
5  NORTH AMERICA MARKET SEGMENT
    5.1 Region Segmentation (2017 to 2021f)
        5.1.1 U.S.
        5.1.2 Canada
        5.1.3 Mexico
    5.2 Product Type Segmentation (2017 to 2021f)
        5.2.1 Ursodeoxycholic Acid (UDCA)
        5.2.2 Obeticholic Acid (Ocaliva)
    5.3 Consumption Segmentation (2017 to 2021f)
        5.3.1 Hospitals
        5.3.2 Clinics
        5.3.3 Others
    5.4 Impact of COVID-19 in North America
6  EUROPE MARKET SEGMENTATION
    6.1 Region Segmentation (2017 to 2021f)
        6.1.1 Germany
        6.1.2 UK
        6.1.3 France
        6.1.4 Italy
        6.1.5 Rest of Europe
    6.2 Product Type Segmentation (2017 to 2021f)
        6.2.1 Ursodeoxycholic Acid (UDCA)
        6.2.2 Obeticholic Acid (Ocaliva)
    6.3 Consumption Segmentation (2017 to 2021f)
        6.3.1 Hospitals
        6.3.2 Clinics
        6.3.3 Others
    6.4  Impact of COVID-19 in Europe
7  ASIA-PACIFIC MARKET SEGMENTATION
    7.1 Region Segmentation (2017 to 2021f)
        7.1.1 China
        7.1.2 India
        7.1.3 Japan
        7.1.4 South Korea
        7.1.5 Southeast Asia
        7.1.6 Australia
        7.1.7 Rest of Asia Pacific
    7.2 Product Type Segmentation (2017 to 2021f)
        7.2.1 Ursodeoxycholic Acid (UDCA)
        7.2.2 Obeticholic Acid (Ocaliva)
    7.3 Consumption Segmentation (2017 to 2021f)
        7.3.1 Hospitals
        7.3.2 Clinics
        7.3.3 Others
    7.4  Impact of COVID-19 in Europe
8  SOUTH AMERICA MARKET SEGMENTATION
    8.1 Region Segmentation (2017 to 2021f)
        8.1.1 Brazil
        8.1.2 Argentina
        8.1.3 Rest of Latin America
    8.2 Product Type Segmentation (2017 to 2021f)
        8.2.1 Ursodeoxycholic Acid (UDCA)
        8.2.2 Obeticholic Acid (Ocaliva)
    8.3 Consumption Segmentation (2017 to 2021f)
        8.3.1 Hospitals
        8.3.2 Clinics
        8.3.3 Others
    8.4  Impact of COVID-19 in Europe
9  MIDDLE EAST AND AFRICA MARKET SEGMENTATION
    9.1 Region Segmentation (2017 to 2021f)
        9.1.1 GCC
        9.1.2 North Africa
        9.1.3 South Africa
        9.1.4 Rest of Middle East and Africa
    9.2 Product Type Segmentation (2017 to 2021f)
        9.2.1 Ursodeoxycholic Acid (UDCA)
        9.2.2 Obeticholic Acid (Ocaliva)
    9.3 Consumption Segmentation (2017 to 2021f)
        9.3.1 Hospitals
        9.3.2 Clinics
        9.3.3 Others
    9.4  Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
    10.1 Brief Introduction of Major Players
        10.1.1 Novartis
        10.1.2 Bristol-Myers Squibb
        10.1.3 Pfizer
        10.1.4 GlaxoSmithKline
        10.1.5 Teva Pharmaceutical
        10.1.6 Retrophin
        10.1.7 Lumena Pharmaceuticals
        10.1.8 Intercept Pharmaceuticals
    10.2  Primary Biliary Cholangitis Treatment Sales Date of Major Players (2017-2020e)
        10.2.1 Novartis
        10.2.2 Bristol-Myers Squibb
        10.2.3 Pfizer
        10.2.4 GlaxoSmithKline
        10.2.5 Teva Pharmaceutical
        10.2.6 Retrophin
        10.2.7 Lumena Pharmaceuticals
        10.2.8 Intercept Pharmaceuticals
    10.3  Market Distribution of Major Players
    10.4 Global Competition Segmentation
11  MARKET FORECAST
    11.1  Forecast by Region
    11.2  Forecast by Demand
    11.3  Environment Forecast
        11.3.1  Impact of COVID-19
        11.3.2  Geopolitics Overview
        11.3.3  Economic Overview of Major Countries
12  REPORT SUMMARY STATEMENT
List of Table
1.Table Primary Biliary Cholangitis Treatment Product Type Overview
2.Table Primary Biliary Cholangitis Treatment Product Type Market Share List
3.Table Primary Biliary Cholangitis Treatment Product Type of Major Players
4.Table Brief Introduction of Novartis
5.Table Brief Introduction of Bristol-Myers Squibb
6.Table Brief Introduction of Pfizer
7.Table Brief Introduction of GlaxoSmithKline
8.Table Brief Introduction of Teva Pharmaceutical
9.Table Brief Introduction of Retrophin
10.Table Brief Introduction of Lumena Pharmaceuticals
11.Table Brief Introduction of Intercept Pharmaceuticals
12.Table Products & Services of Novartis
13.Table Products & Services of Bristol-Myers Squibb
14.Table Products & Services of Pfizer
15.Table Products & Services of GlaxoSmithKline
16.Table Products & Services of Teva Pharmaceutical
17.Table Products & Services of Retrophin
18.Table Products & Services of Lumena Pharmaceuticals
19.Table Products & Services of Intercept Pharmaceuticals
20.Table Market Distribution of Major Players
21.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
22.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
23.Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) by Region 2021f-2026f
24.Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
25.Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) by Demand 2021f-2026f
26.Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f
List of Figure
1.Figure Global Primary Biliary Cholangitis Treatment Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2.Figure Global Primary Biliary Cholangitis Treatment Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3.Figure Global Primary Biliary Cholangitis Treatment Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4.Figure Global Primary Biliary Cholangitis Treatment Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5.Figure Global Primary Biliary Cholangitis Treatment Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6.Figure Global Primary Biliary Cholangitis Treatment Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7.Figure Global Primary Biliary Cholangitis Treatment Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8.Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9.Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10.Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11.Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12.Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13.Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14.Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15.Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16.Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18.Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
19.Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20.Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21.Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22.Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23.Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24.Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26.Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27.Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28.Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29.Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30.Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31.Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32.Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33.Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34.Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36.Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37.Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38.Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
39.Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
40.Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
41.Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
42.Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
43.Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
44.Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
45.Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
46.Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
47.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
48.Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
49.Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
50.Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
51.Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
52.Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
53.Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
54.Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
55.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
56.Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
57.Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
58.Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59.Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60.Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61.Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62.Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63.Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Novartis 2017-2020e
66.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Bristol-Myers Squibb 2017-2020e
67.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Pfizer 2017-2020e
68.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of GlaxoSmithKline 2017-2020e
69.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Teva Pharmaceutical 2017-2020e
70.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Retrophin 2017-2020e
71.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Lumena Pharmaceuticals 2017-2020e
72.Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Intercept Pharmaceuticals 2017-2020e
73.
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Primary Biliary Cholangitis Treatment Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Primary Biliary Cholangitis Treatment Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Primary Biliary Cholangitis Treatment Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports